Burney CO Exelixis, Inc. Transaction History

Burney CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$18.17 - $20.48 $2.04 Million - $2.3 Million	112,489 New	112,489 $2.15 Million
Q4 2021 Feb 11, 2022	SELL	$15.84 - $21.88 $328,664 - $453,988	-20,749 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $148,281 - $192,310	-9,097 Reduced 30.48%	20,749 $439,000
Q2 2021 Aug 06, 2021	SELL	$17.95 - $25.56 $8,705 - $12,396	-485 Reduced 1.6%	29,846 $544,000
Q1 2021 May 13, 2021	SELL	$20.53 - $25.22 $87,334 - $107,285	-4,254 Reduced 12.3%	30,331 $685,000
Q4 2020 Feb 11, 2021	SELL	$18.39 - $24.8 $2.65 Million - $3.58 Million	-144,280 Reduced 80.66%	34,585 $694,000
Q3 2020 Dec 14, 2020	BUY	$20.67 - $26.94 $548,333 - $714,664	26,528 Added 17.41%	178,865 $4.37 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $2.51 Million - $4.18 Million	152,337 New	152,337 $3.62 Million

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Burney CO, based on Form 13F filings with the SEC.

Stay updated on Burney CO with notifications on news.